去纤维钠国内买的到吗？

(Alias: defibrotide) is used to treat hepatic veno-occlusive disease (VOD), not only for adult patients, but also for pediatric patients. The recommended dose for adult and pediatric patients is 6.25 mg/kg given as a 2-hour intravenous infusion every 6 hours. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Administer defibrinated sodium for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue until resolution of VOD or up to a maximum of 60 days. Defibrinated sodium must be diluted before infusion.

For some patients with leukemia and lymphoma, hematopoietic stem cell transplantation (HSCT) is the only hope to cure the disease and regain health. Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. The launch of defibrotide sodium (defibrotide) has brought new options for the treatment of this rare disease. In clinical trials, patients used 5 to 60 mg/kg of defibrinated sodium as intravenous infusion every day. The results showed that 42% of patients achieved complete remission (CR), and the overall survival (os) rate 100 days after transplantation reached 32%.

Is fiber-reduced sodium available in China?

Only drugs that have been approved for marketing in my country can be purchased domestically. However, they are not currently on the market in my country, so they cannot be purchased domestically. Patients can only purchase foreign versions. It is understood that the price of defibrotide sodium (defibrinoside) when marketed overseas is about RMB 22,000. As an orphan drug, defibrination sodium is also difficult to purchase. If it is inconvenient for patients to go abroad, then the domestic formal overseas medical consulting service company - Medical Companion Travel will be a good choice.

Recommended related hot articles: /newsDetail/71748.html